Sweden · Delayed Price · Currency is SEK Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of SEK 442.33 million. The enterprise value is 509.30 million.
| Market Cap | 442.33M |
| Enterprise Value | 509.30M |
Important Dates
The last earnings date was Thursday, February 19, 2026.
| Earnings Date | Feb 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncopeptides AB has 272.71 million shares outstanding. The number of shares has increased by 36.32% in one year.
| Current Share Class | 258.57M |
| Shares Outstanding | 272.71M |
| Shares Change (YoY) | +36.32% |
| Shares Change (QoQ) | +15.59% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 10.87% |
| Float | 256.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.22 |
| PB Ratio | -7.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.04 |
| EV / Sales | 7.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.63
| Current Ratio | 2.63 |
| Quick Ratio | 2.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.55 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -74.09% |
| Return on Invested Capital (ROIC) | -98.07% |
| Return on Capital Employed (ROCE) | -248.68% |
| Weighted Average Cost of Capital (WACC) | -0.69% |
| Revenue Per Employee | 948,240 |
| Profits Per Employee | -3.33M |
| Employee Count | 75 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.39 |
Taxes
In the past 12 months, Oncopeptides AB has paid 1.42 million in taxes.
| Income Tax | 1.42M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.88% in the last 52 weeks. The beta is -1.70, so Oncopeptides AB's price volatility has been lower than the market average.
| Beta (5Y) | -1.70 |
| 52-Week Price Change | +1.88% |
| 50-Day Moving Average | 3.40 |
| 200-Day Moving Average | 4.00 |
| Relative Strength Index (RSI) | 22.42 |
| Average Volume (20 Days) | 2,180,364 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of SEK 71.12 million and -249.59 million in losses. Loss per share was -1.10.
| Revenue | 71.12M |
| Gross Profit | 68.67M |
| Operating Income | -224.65M |
| Pretax Income | -248.17M |
| Net Income | -249.59M |
| EBITDA | -222.18M |
| EBIT | -224.65M |
| Loss Per Share | -1.10 |
Balance Sheet
The company has 82.26 million in cash and 149.23 million in debt, with a net cash position of -66.97 million or -0.25 per share.
| Cash & Cash Equivalents | 82.26M |
| Total Debt | 149.23M |
| Net Cash | -66.97M |
| Net Cash Per Share | -0.25 |
| Equity (Book Value) | -58.89M |
| Book Value Per Share | -0.22 |
| Working Capital | 72.66M |
Cash Flow
| Operating Cash Flow | -216.49M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 96.55% |
| Operating Margin | -315.88% |
| Pretax Margin | -348.96% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.32% |
| Shareholder Yield | -36.32% |
| Earnings Yield | -56.43% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |